 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. Lucid, has entered into a clinical trial research agreement with the University of Pennsylvania Penn for a clinical trial designed to evaluate whether Lucids EsoCheckTM Esophageal Cell Collection Device with CollectProtectTM Technology EsoCheck provides a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies in the management of patients with Eosinophilic Esophagitis. Eosinophilic esophagitis EoE is a rapidly emerging allergy-mediated inflammatory condition of the esophagus similar to and often associated with inflammatory bowel disease IBD. 